At 22.1% CAGR, the Europe Organoids Market is Projected to be Worth US$ 5,016.03 Million by 2031, Says Business Market Insights

According to Business Market Insights research, the Europe organoids market was valued at US$ 1,018.12 million in 2023 and is expected to reach US$ 5,016.03 million by 2031, registering a CAGR of 22.1% from 2023 to 2031. Surging adoption of personalized drugs and focus on drug discovery activities are among the critical factors attributed to the Europe organoids market expansion.

Personalized medicine, also known as precision medicine, is a medical model that practices procedures or drugs that are tailored to the individual patient based on the anticipated response or disease risk.

The growing demand for personalized medicine in Europe is significantly shaping the development and use of organoid technologies, especially in oncology and genetic disorders. A notable example of this innovation is the collaboration between King's College London and GSK, where researchers are creating patient-derived lung cancer organoids to predict relapse and identify effective treatment combinations. These organoids reflect the unique genetic mutations present in each patient's cancer, enabling tailored therapy selection.

Moreover, the European Medicines Agency (EMA) has acknowledged the significance of organoid technology in precision medicine. The EMA's adaptive pathways initiative supports the use of innovative methods like organoids to expedite the approval process for new therapies, thereby facilitating the transition from research to clinical application.

Pharmacists play an essential role in propelling the demand for personalized medicines as they proactively create awareness about precision medicine. The increasing demand has persuaded pharmaceutical enterprises to develop more tailored treatments to make medicines safer and more effective. Personalized cancer medicine revolves around tailoring effective therapeutic strategies for each patient according to the genomic characterization of their tumor. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in preclinical settings. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine to investigate treatments based on gene–drug associations, identify new therapies, and predict patient outcomes. The use of personalized tumor models with similar characteristics to the original tumors may result in accurate predictions of drug responses in patients. The preservation of the molecular and cellular composition of an original tumor is a significant advantage of tumor organoid models over pre-existing models. Thus, the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens, fuels the organoids market growth.

On the contrary, dearth of skilled professionals hampers the growth of Europe organoids market.

Based on type, the Europe organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held 23.2% share of the Europe organoids market in 2023, amassing US$ 235.74 million. It is projected to garner US$ 1,140.24 million by 2031 to expand at 21.8% CAGR during 2023–2031.

Based on application, the Europe organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held 29.6% share of the Europe organoids market in 2023, amassing US$ 301.52 million. It is projected to garner US$ 1,554.86 million by 2031 to expand at 22.8% CAGR during 2023–2031.

Based on source, the Europe organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held 72.8% share of the Europe organoids market in 2023, amassing US$ 740.70 million. It is projected to garner US$ 3,763.97 million by 2031 to expand at 22.5% CAGR during 2023–2031.

Based on offering, the Europe organoids market is segmented into instruments, consumables, and services. The consumables segment held 57.0% share of the Europe organoids market in 2023, amassing US$ 579.85 million. It is projected to garner US$ 2,852.82 million by 2031 to expand at 22.0% CAGR during 2023–2031. The instruments segment is further sub segmented into devices and equipment. The consumables segment is further sub segmented into sensors and others.

Based on method, the Europe organoids market is segmented into micropatterned plates, ultralow attachment plates, hanging drop, microdroplet or emulsion, and others. The hanging drop segment held 43.8% share of the Europe organoids market in 2023, amassing US$ 445.60 million. It is projected to garner US$ 2,139.33 million by 2031 to expand at 21.7% CAGR during 2023–2031.

Based on country, the Europe organoids market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Germany held 29.2% share of Europe organoids market in 2023, amassing US$ 297.09 million. It is projected to garner US$ 1,447.63 million by 2031 to expand at 21.9% CAGR during 2023–2031.

Key players operating in the organoids market are STEMCELL Technologies Inc; Molecular Devices, LLC.; Hubrecht Organoid Technology; Definigen; Organoid Therapeutics; Thermo Fisher Scientific Inc; Corning Inc; Merck KGaA; InSphero; ACRO Biosystems; Bio-Techne Corp; SUN bioscience SA; ORGANOID SCIENCES Co., Ltd.; Crown Bioscience Inc; Sartorius AG; 3D Biotek LLC; Prellis Biologics Inc.; 3Dnamics Inc.; and Cellesce Ltd, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com